Results 61 to 70 of about 124,134 (216)

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala, Sophie Peigné, Michael Chargualaf, Zoey Tang, Diansong Zhou, Naoyuki Tajima, Malaz Abutarif, Tushar Garimella   +10 more
wiley   +1 more source

Model‐based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications

Clinical Pharmacology &Therapeutics, EarlyView.
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Yue Zhao, Zheyi Hu, Elizabeth Gibson, Li Zhu, Heather Vezina, Anna G. Kondic   +5 more
wiley   +1 more source

Proportion, Five‐Year Survival Rate of Laryngeal Cancer and Its Associated Factors Among Head and Neck Cancer Patients in Tanzania

Eye &ENT Research, EarlyView.
ABSTRACT Background Laryngeal cancer carries a significant global burden, with substantial morbidity and mortality, and is increasing globally, with 95%–98% being squamous cell carcinoma. Males are more affected than females, with peak cases occurring between 60 and 80 years of age.
Amenye Adili, Furaha Serventi, Baraka M. Musimu, Mica Magembe, Orest Tarimo, Geofrey Ikelesho, Salum Kalonge, Leonard Kiboko, Queen Godfrey Tarimo, Desderius C. Chussi   +9 more
wiley   +1 more source

Genetic variants of EcPV2 E6 and E7 in equine genital and oronasal squamous cell carcinoma

Equine Veterinary Journal, EarlyView.
Abstract Background Since its discovery in 2008, equine papillomavirus type 2 (EcPV2) has been detected in up to 100% of equine genital and up to 40% of equine oronasal squamous cell carcinomas (SCCs). Preliminary sequence data point to the existence of EcPV2 E6 and E7 oncogene variants compared to the British reference sequence from 2008.
Maya Jenner, Sabine Brandt
wiley   +1 more source

Detection of Human Herpesvirus Type-1 Antigen in Tissues of Oral Squamous Cell Carcinoma by Direct Immunofluorecent Assay

Diyala Journal of Medicine, 2019
Background: Human herpesvirus is a large enveloped DNA virus and significant human pathogen. Many studies examined oral squamous cell carcinoma for herpes simplex virus and suggested an association with this virus; others have demonstrated human ...
Najwa Ahmed Mohammed, Areej Atiyah Hussein, Ahlam Hameed Majeed   +2 more
doaj   +2 more sources

Dental Rehabilitation of the Scapular Tip in Maxillary Reconstruction

Head &Neck, EarlyView.
ABSTRACT Introduction The fibula‐free flap has traditionally been utilized to perform dental rehabilitation following maxillectomy. The purpose of this study is to present our experience with dental implantation of the scapula–tip‐free flap in midface reconstruction.
Leba M. Sarkis, John Lee, Karl Cuddy, Brian Rittenberg, Majd Al Mardini, Christopher MKL Yao, Sharon Tzelnick, David Goldstein, Ralph Gilbert, John R. de Almeida   +9 more
wiley   +1 more source

A Comparative Study of Bcl-2 Expression in Oral Leukoplakia with Dysplasia, Verrucous Carcinoma, and Oral Squamous Cell Carcinoma

Journal of Pharmacy and Bioallied Sciences
Aim: To study the immunohistochemical expression of Bcl-2 in oral leukoplakia with dysplasia, verrucous carcinoma and oral squamous cell carcinoma(OSCC).
Bireswar Roy, Shivani Saxena, Narayan Tripathi, Mridul Sharma, Deepmala Rana, N Pramukh, Miral Mehta   +6 more
doaj   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

Downregulation of Notch4 – a prognostic marker in distinguishing oral verrucous carcinoma from oral squamous cell carcinoma

Brazilian Journal of Otorhinolaryngology, 2019
Introduction: Oral verrucous carcinoma is a special form of well-differentiated squamous cell carcinoma which possesses specific clinical, morphologic and cytokinetic features that differ from other types of oral cancers and hence diagnosis requires ...
M.K. Harishankar, A. Mathan Mohan, A. Vinod Krishnan, Arikketh Devi   +3 more
doaj   +1 more source

Fluorescence‐Guided Detection of Perineural and Bony Invasion With Margin Correlation in Gingival Squamous Cell Carcinoma Using Panitumumab‐IRDye800

Head &Neck, EarlyView.
ABSTRACT Background Near‐infrared (NIR) fluorescence‐guided surgery using EGFR‐targeted tracers (e.g., panitumumab‐IRDye800CW) can provide real‐time visualization of tumors and margins in Head and Neck Squamous Cell Carcinoma. Prior studies have demonstrated its safety and potential to improve intraoperative decision‐making and margin assessment ...
Makenna Brown, Mabrooka Kazi, Hidenori Tanaka, Brandee Brown, Mitra Mehrad, Sarah Rohde, Eben Rosenthal, Kyle Mannion   +7 more
wiley   +1 more source